stocks logo

NVO Earnings

Novo Nordisk A/S
$
50.495
+0.715(1.436%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings

Earning Analysis

Welcome to our in-depth analysis of Novo Nordisk A/S(NVO) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Novo Nordisk A/S earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.

Earnings Forecast

Revenue
EPS
Currency: DKK
Actual
Estimate

Surprise Analysis

Name
EPS
Revenue
Price Reaction
Fiscal QuarterEarning DateTimeEstimateActualSurprise%EstimateActualSurprise%1D5D
FY2025Q22025-08-06Pre-Market0.930.97+4.3077.11B76.86B-0.33-3.90+5.61
FY2025Q12025-05-07Pre-Market0.920.92-78.02B78.09B+0.09+1.90+2.19
FY2024Q42025-02-05Pre-Market0.830.91+9.6483.03B85.68B+3.20+3.76+1.36
FY2024Q22024-08-07Pre-Market0.710.65-8.4568.56B68.06B-0.73-8.37+2.65
FY2024Q12024-05-02-0.770.83+7.7963.44B65.35B+3.01-4.02-1.95
FY2023Q42024-01-31-0.660.71+7.5861.21B65.86B+7.61+5.25+7.88
FY2023Q32023-11-02-0.690.73+5.8057.39B58.73B+2.33+3.33+4.18
FY2023Q22023-08-10-1.341.26-5.9755.82B54.30B-2.72-2.93-1.57
-2023-02-01-0.810.83+2.47---+0.22+0.58
-2022-11-02-0.840.86+2.38---+6.39+7.91

NVO Earnings Analysis

Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Novo Nordisk A/S reported performance for FY2025Q2, announced on 2025-08-06. The company achieved an EPS of 0.97, compared to analyst estimates of 0.93 by 4.30% . Revenue for the quarter reached 76.86B compared to expectations of 77.11B by -0.33% .
The stock price reacted with a -3.90% one-day change and a 5.61% five-day change following the earnings release. These movements reflect market reaction in Novo Nordisk A/S growth trajectory and strategic initiatives.

NVO Earnings Forecast

Looking ahead, Novo Nordisk A/S(NVO) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q3 project quarter revenue of 78.03B and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -5.07%, while EPS estimates have been Revise Downward by -5.6%. For the upcoming , revenue estimates have been adjusted Go Down by -22.79% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Novo Nordisk A/S long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

Estimate Revision

The chart shows the correlation between NVO's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Downward
down Image
-5.07%
In Past 3 Month
Revenue Estimates for Q3 2025
Revise Downward
down Image
-5.6%
In Past 3 Month
Stock Price
Go Down
down Image
-22.79%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
--
Revenue Estimate-Annual FY 2025:321.32B
--
EPS Estimate-Annual FY 2025:0
Stock Price50.49

NVO Revenue and EPS Performance: A Historical Perspective

Novo Nordisk A/S revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-08-06,Pre-Market):
EPS: 0.97 (Actual) vs.0.93 (Estimate) (4.30%)
Revenue: 76.86B (Actual) vs. 77.11B (Estimate) (-0.33%)
Price Reaction: -3.90%(1-Day), 5.61%(5-Day)
FY2025Q1 (2025-05-07,Pre-Market):
EPS: 0.92 (Actual) vs.0.92 (Estimate) (0.00%)
Revenue: 78.09B (Actual) vs. 78.02B (Estimate) (0.09%)
Price Reaction: 1.90%(1-Day), 2.19%(5-Day)
FY2024Q4 (2025-02-05,Pre-Market):
EPS: 0.91 (Actual) vs.0.83 (Estimate) (9.64%)
Revenue: 85.68B (Actual) vs. 83.03B (Estimate) (3.20%)
Price Reaction: 3.76%(1-Day), 1.36%(5-Day)
Earnings Reaction
The chart below shows how NVO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NVO sees a +1.71% change in stock price 10 days leading up to the earnings, and a +4.06% change 10 days following the report. On the earnings day itself, the stock moves by +0.16%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed 7.45% on the day following the earnings release and then changed by 11.27% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.

Transcript Summary

Novo Nordisk A/S (NVO) Q2 2025 Earnings Call Summary
Positive
2025-08-06
The earnings call reflects strong financial performance with an 18% sales growth and 20% operating profit increase. The company's strategic initiatives, such as partnerships and market expansions, are promising. While there are some uncertainties in litigation and pricing strategies, management's confidence in growth, particularly in China, and the launch of new products like oral Wegovy, supports a positive outlook. The guidance suggests continued strong performance, and there's optimism in overcoming challenges like LOE impacts. Overall, the sentiment is positive, with potential for stock price appreciation.
Novo Nordisk A/S (NVO) Q1 2025 Earnings Call Summary
Neutral
2025-05-07
The earnings call presents a mixed outlook. Positive aspects include a 20% increase in operating profit, strong net profit growth, and a significant free cash flow increase. However, challenges are evident with a decreased gross margin, increased costs, and a significant net financial loss. The Q&A reveals uncertainties in market share dynamics and competitive pressures, with management providing vague responses. Despite positive shareholder returns, the lack of clear guidance and potential competitive risks balance the positives, leading to a neutral sentiment.
Novo Nordisk A/S (NVO) Q3 2024 Earnings Call Summary
Positive
2024-11-06
The earnings call reveals strong sales and operating profit growth, a slight gross margin increase, and an optimistic sales growth outlook. However, concerns about regulatory risks, increased competition, and a significant impairment loss slightly temper the outlook. The Q&A section shows confidence in future growth, despite some uncertainties about product timelines. The share buyback program and raised guidance further support a positive sentiment. Overall, the positive financial performance and optimistic guidance outweigh the risks, suggesting a positive stock price movement in the near term.
Novo Nordisk A/S (NVO) Q2 2024 Earnings Call Summary
Positive
2024-08-07
The earnings call presents a mixed picture with strong sales and operating profit growth, increased shareholder returns, and positive updates on product development and market strategy. However, there are concerns about increased costs, impairment losses, and hedging losses. The Q&A section reveals management's optimism about future growth and stable competitive dynamics, despite some evasive responses. The overall sentiment is positive, supported by increased dividends and strategic expansions, suggesting a likely positive stock price movement in the short term.

FAQ

arrow icon

What were the key highlights of NVO’s latest earnings report for FY2025Q2?

NVO reported its FY2025Q2 earnings on 2025-08-06, showcasing a revenue of 76.86B against an estimate of 77.11B, resulting in a -0.33% surprise. The EPS was 0.97, surpassing the expected 0.93 by 4.3% . The stock experienced a -3.9% price change on the earnings day and a 5.61% change over the next five days, reflecting market reactions to the results.
arrow icon

How did NVO’s stock price react after the FY2025Q2 earnings release?

arrow icon

What are the revenue and EPS estimates for NVO for 2025/Q3?

arrow icon

How does NVO’s stock price correlate with earnings forecast revisions?

arrow icon

What should investors expect from NVO’s next earnings report?

arrow icon

What is the sentiment in Novo Nordisk A/S (NVO) Q2 2025 Earnings Call Summary?